FIELD OF THE INVENTION
The invention is in the field of pharmaceutical compositions which are useful for the prevention and/or treatment of neurodegradation and other neuropathological conditions in animals.
BACKGROUND OF THE INVENTION
The amino acid L-glutamate is widely thought to act as a
FIELD OF THE INVENTION
The invention is in the field of pharmaceutical compositions which are useful for the prevention and/or treatment of neurodegradation and other neuropathological conditions in animals.
BACKGROUND OF THE INVENTION
The amino acid L-glutamate is widely thought to act as a
TECHNICAL FIELD
The present disclosure relates to novel crystalline acid salts of a tricyclic derivative or a hydrate thereof, and a production method thereof.
BACKGROUND
Drugs administered orally show medicinal effects through absorption, distribution, metabolism or elimination, and the intrinsic
This application is a U.S. National Stage application of co-pending PCT application PCT/GB2004/002755, filed Jun. 24, 2004, which claims the priority of Great Britain Patent Application No. 0315111.5, filed Jun. 27, 2003. These applications are incorporated herein by reference in their
BACKGROUND OF THE INVENTION
This invention relates to N,N'-disubstituted guanidine analogues, and to compounds and pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods for treating any disease of the nervous system in
FIELD OF THE INVENTION
This invention is in the field of medicinal chemistry. In particular, this invention relates to N,N'-disubstituted guanidine analogues, and to compounds and pharmaceutical composition comprising the same, which possess neuroprotective capability. This invention further relates
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
This invention relates to novel branched adamantyl, noradamantyl aryl and aralkylpiperazines having serotonin 5-HT.sub.1A activity. More particularly, the present invention relates to compounds and methods using them to provide neuroprotection and prevent, inhibit or limit processes of
This invention relates to novel branched adamantyl, noradamantyl aryl and aralkylpiperazines having serotonin 5-HT.sub.1A activity. More particularly, the present invention relates to compounds and methods using them to provide neuroprotection and prevent, inhibit or limit processes of
The most complete medicinal herbs database backed by science
Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against. *All information is based on published scientific research